EMERYVILLE, Calif., Nov 14, 2024 — Amyris, Inc., a vertically integrated synthetic biology company and leading innovator in the field of industrial biotechnology, today announced the approval of the company’s 2030 Strategic Plan by its Board of Directors, as well as additional funding from its long-term investor.
“We are very excited about the what the future holds for Amyris,” said Kathy Fortmann, Amyris’ Chief Executive Officer. “We are grateful to have an investor who is committed to the company’s objective of Innovating to profitably deliver clean molecules to the world, with shared values and confidence in our plan. We are also grateful for our existing key partners for their continued support. We are encouraged by the positive conversations we’ve been having with potential new partners about what we offer the market and our continued leadership – and unique position – in the industry.”
The company will be sharing details about its 2030 Strategic Plan in the weeks to come.
About Amyris
Amyris is a vertically integrated, synthetic biology company that creates sustainable, market-ready ingredients utilizing proprietary advanced precision fermentation technology and world-class platforms. Leveraging two decades of experience, Amyris collaborates with companies to co-create innovative ingredients at unprecedented speed and scale. This enables partners to deliver products with differentiated performance that meet sustainability and economic objectives. Its renewable and traceable ingredients are included in thousands of products from the world’s top brands, reaching millions of consumers. For more information, please visit http://www.amyris.com.
Amyris, Inc., a vertically integrated synthetic biology company and leading innovator in the field of industrial biotechnology, today announced the approval of the company’s 2030 Strategic Plan by its Board of Directors, as well as additional funding from its long-term investor.
“We are very excited about the what the future holds for Amyris,” said Kathy Fortmann, Amyris’ Chief Executive Officer. “We are grateful to have an investor who is committed to the company’s objective of Innovating to profitably deliver clean molecules to the world, with shared values and confidence in our plan. We are also grateful for our existing key partners for their continued support. We are encouraged by the positive conversations we’ve been having with potential new partners about what we offer the market and our continued leadership – and unique position – in the industry.”
The company will be sharing details about its 2030 Strategic Plan in the weeks to come.
About Amyris
Amyris is a vertically integrated, synthetic biology company that creates sustainable, market-ready ingredients utilizing proprietary advanced precision fermentation technology and world-class platforms. Leveraging two decades of experience, Amyris collaborates with companies to co-create innovative ingredients at unprecedented speed and scale. This enables partners to deliver products with differentiated performance that meet sustainability and economic objectives. Its renewable and traceable ingredients are included in thousands of products from the world’s top brands, reaching millions of consumers. For more information, please visit http://www.amyris.com.
Amyris Media Contact:
Corporate Communications
Email: [email protected]
Website: https://amyris.com/
Corporate Communications
Email: [email protected]
Website: https://amyris.com/